Original articleAnalysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
Section snippets
PharMetrics sample selection
In this retrospective analysis, health care claims data were gathered from the PharMetrics Integrated Database, which contains financial claims filed for reimbursement for patients enrolled in 1 of more than 90 managed care organizations or covered under employer health plans or those of family members.16 Patients who were included in the final population sample had been continuously enrolled in a health care plan the entire year of 2007. We derived 4 case definitions for HS because of the lack
Clinical and demographic characteristics of the PharMetrics HS population
Of the 15,054,519 members of the PharMetrics database with continuous enrollment across the 12 months of 2007, 7927 (0.053%) patients met at least 1 of the case definitions. The mean age (SD) was 38.2 (14.73) years, and 5834 (74%) patients were women (Table II). As shown in Table II, case definition 1 (ICD-9-CM diagnosis only) identified 7275 (92%) patients, whereas case definition 2 (CPT procedure only) contributed 101 (1%) patients. Case definition 3 (ICD-9-CM diagnosis and CPT procedure)
Discussion
This was a systematic investigation of HS in a large population in the United States. The rate of clinically detected HS was low (0.053% or an estimated total number of 146,000-162,000 patients in the United States in 2007), its affected persons were almost 3 times as likely to be female rather than male, and the prevalence was highest in those aged 18 to 44 years. The higher prevalence among women could be a result of higher use of health care19; the sex differential reported here is
References (23)
- et al.
Hidradenitis suppurativa: a comprehensive review
J Am Acad Dermatol
(2009) - et al.
Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies
J Am Acad Dermatol
(2008) - et al.
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial
J Am Acad Dermatol
(2010) - et al.
The prevalence of hidradenitis suppurativa and its potential precursor lesions
J Am Acad Dermatol
(1996) Yield from a complete skin examination: findings in 1157 new dermatology patients
J Am Acad Dermatol
(1988)- et al.
Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity
J Am Acad Dermatol
(2009) - et al.
Hidradenitis suppurativa
Br J Surg
(2009) - et al.
Acne inversa
Int J Dermatol
(1998) - et al.
TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future
QJM
(2010) - et al.
Recurrence after surgical treatment of hidradenitis suppurativa
Br Med J
(1987)
Psychophysical aspects of hidradenitis suppurativa
Acta Derm Venereol
Cited by (145)
Differentiating hidradenitis suppurativa flare from infection in the emergency department and recommendations for transitioning care to the outpatient setting
2024, American Journal of Emergency MedicineEpidemiology of hidradenitis suppurativa
2023, Clinics in DermatologyMucosal-Associated Invariant T Cells Are Altered in Patients with Hidradenitis Suppurativa and Contribute to the Inflammatory Milieu
2023, Journal of Investigative DermatologyCitation Excerpt :Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition which affects up to 4% of the population, resulting in the development of nodules and abscesses in apocrine-bearing skin of the axillae, groin, buttocks and the inframammary fold(Cosmatos et al., 2013).
Hidradenitis Suppurativa Epidemiology
2022, A Comprehensive Guide to Hidradenitis SuppurativaPediatric Hidradenitis Suppurativa
2022, A Comprehensive Guide to Hidradenitis Suppurativa
Ms Cosmatos is currently affiliated with IMS Health Inc, Parsippany, NJ.
Supported by Janssen Services LLC.
Disclosure: Dr Montgomery was an employee of Janssen Services LLC, at the time of this research, and Dr Stang, Ms Cosmatos, Ms Matcho, and Dr Weinstein are or were employees of Janssen Research and Development LLC.
Conflicts of interest: None declared.